Effects of ADIPOQ and NOS3 SNPs/haplotypes on blood pressure control in patients with adherence to antihypertensive therapy
Aim: We examined whether ADIPOQ (rs266729 and rs1501299) and NOS3 (rs3918226 and rs1799983) SNPs or the haplotypes formed by them, affect blood pressure (BP) control in 196 patients with adherence to antihypertensive therapy grouped into controlled (BP <140/90 mmHg) and uncontrolled (BP ≥140/90 mmHg) hypertension. Materials & methods: The average of the three most recent BP measurements was retrieved from the patients' electronic medical records. Adherence to antihypertensive therapy was evaluated using the Morisky-Green test. Haplotype frequencies were estimated using Haplo.stats. Multiple logistic/linear regression analyses were adjusted for the covariates ethnicity, dyslipidemia, obesity, cardiovascular disease and uric acid. Results: ADIPOQ rs266729 genotypes CG (additive model) and CG+GG (dominant model) were associated with uncontrolled hypertension and CG was associated with higher systolic BP and mean arterial pressure (p < 0.05). ADIPOQ haplotypes 'GT' and 'GG' were associated with uncontrolled hypertension and 'GT' was associated with higher diastolic BP and mean arterial pressure (p < 0.05). Conclusion: ADIPOQ SNPs and haplotypes affect BP control in hypertensive patients undergoing treatment.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
---|---|
Enthalten in: |
Pharmacogenomics - 24(2023), 5 vom: 03. Apr., Seite 269-281 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Cunha, Warlley R [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 18.04.2023 Date Revised 09.05.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.2217/pgs-2023-0012 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM355190923 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM355190923 | ||
003 | DE-627 | ||
005 | 20231226063825.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.2217/pgs-2023-0012 |2 doi | |
028 | 5 | 2 | |a pubmed24n1183.xml |
035 | |a (DE-627)NLM355190923 | ||
035 | |a (NLM)37014323 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Cunha, Warlley R |e verfasserin |4 aut | |
245 | 1 | 0 | |a Effects of ADIPOQ and NOS3 SNPs/haplotypes on blood pressure control in patients with adherence to antihypertensive therapy |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 18.04.2023 | ||
500 | |a Date Revised 09.05.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Aim: We examined whether ADIPOQ (rs266729 and rs1501299) and NOS3 (rs3918226 and rs1799983) SNPs or the haplotypes formed by them, affect blood pressure (BP) control in 196 patients with adherence to antihypertensive therapy grouped into controlled (BP <140/90 mmHg) and uncontrolled (BP ≥140/90 mmHg) hypertension. Materials & methods: The average of the three most recent BP measurements was retrieved from the patients' electronic medical records. Adherence to antihypertensive therapy was evaluated using the Morisky-Green test. Haplotype frequencies were estimated using Haplo.stats. Multiple logistic/linear regression analyses were adjusted for the covariates ethnicity, dyslipidemia, obesity, cardiovascular disease and uric acid. Results: ADIPOQ rs266729 genotypes CG (additive model) and CG+GG (dominant model) were associated with uncontrolled hypertension and CG was associated with higher systolic BP and mean arterial pressure (p < 0.05). ADIPOQ haplotypes 'GT' and 'GG' were associated with uncontrolled hypertension and 'GT' was associated with higher diastolic BP and mean arterial pressure (p < 0.05). Conclusion: ADIPOQ SNPs and haplotypes affect BP control in hypertensive patients undergoing treatment | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a ADIPOQ | |
650 | 4 | |a NOS3 | |
650 | 4 | |a adiponectin | |
650 | 4 | |a antihypertensive | |
650 | 4 | |a haplotypes | |
650 | 4 | |a hypertension | |
650 | 4 | |a medication adherence | |
650 | 4 | |a nitric oxide | |
650 | 4 | |a pharmacogenetics | |
650 | 4 | |a polymorphims | |
650 | 7 | |a Antihypertensive Agents |2 NLM | |
650 | 7 | |a Adiponectin |2 NLM | |
650 | 7 | |a NOS3 protein, human |2 NLM | |
650 | 7 | |a EC 1.14.13.39 |2 NLM | |
650 | 7 | |a Nitric Oxide Synthase Type III |2 NLM | |
650 | 7 | |a EC 1.14.13.39 |2 NLM | |
650 | 7 | |a ADIPOQ protein, human |2 NLM | |
700 | 1 | |a Agostini, Lívia C |e verfasserin |4 aut | |
700 | 1 | |a Dos Moreira, Wellington Ms |e verfasserin |4 aut | |
700 | 1 | |a M Teixeira, Luiz Fernando |e verfasserin |4 aut | |
700 | 1 | |a Vital, Wendel C |e verfasserin |4 aut | |
700 | 1 | |a da Silva, Glenda N |e verfasserin |4 aut | |
700 | 1 | |a Silva, Nayara Nt |e verfasserin |4 aut | |
700 | 1 | |a Luizon, Marcelo R |e verfasserin |4 aut | |
700 | 1 | |a Oliveira-Paula, Gustavo H |e verfasserin |4 aut | |
700 | 1 | |a Lima, Angélica A |e verfasserin |4 aut | |
700 | 1 | |a Belo, Vanessa A |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Pharmacogenomics |d 2000 |g 24(2023), 5 vom: 03. Apr., Seite 269-281 |w (DE-627)NLM111671396 |x 1744-8042 |7 nnns |
773 | 1 | 8 | |g volume:24 |g year:2023 |g number:5 |g day:03 |g month:04 |g pages:269-281 |
856 | 4 | 0 | |u http://dx.doi.org/10.2217/pgs-2023-0012 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 24 |j 2023 |e 5 |b 03 |c 04 |h 269-281 |